Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Objective We sought to investigate the long-term outcomes of patients who develop immune
checkpoint inhibitor (ICI)-induced inflammatory arthritis (IA), to define factors associated with …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Autoimmune diabetes mellitus is a rare but significant side effect of treatment with immune
checkpoint inhibitors. Immune checkpoint inhibitor-induced diabetes mellitus (CPI-DM) is …

Immune checkpoint inhibitors (ICIs) block inhibitory molecules, such as cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or its …

Current cancer immunotherapies target immune checkpoint molecules such as the inhibitory
receptor programmed cell death-1 (PD-1), one of its ligands, programmed cell death ligand …

Immune checkpoint inhibitors (ICIs) have now been approved in numerous and diverse
cancer types and combination regimens. Effective recognition and treatment of ICI toxicities …